N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide
Encyclopedia
7-methoxy-1--N-((1S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (N-[(S)-fenchyl]-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide) is a drug invented by Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb , often referred to as BMS, is a pharmaceutical company, headquartered in New York City. The company was formed in 1989, following the merger of its predecessors Bristol-Myers and the Squibb Corporation...

, that acts as a reasonably selective agonist
Agonist
An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Agonists often mimic the action of a naturally occurring substance...

 of peripheral cannabinoid receptor
Cannabinoid receptor
The cannabinoid receptors are a class of cell membrane receptors under the G protein-coupled receptor superfamily. As is typical of G protein-coupled receptors, the cannabinoid receptors contain seven transmembrane spanning domains...

s. It has moderate affinity for CB2 receptors with a Ki of 11nM, but 22x lower affinity for the psychoactive CB1 receptors with a Ki of 245nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with a Ki of 8nM at CB1 and 29nM at CB2, which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB2 (cf. JWH-018
JWH-018
JWH-018 or AM-678 is an analgesic chemical from the naphthoylindole family, which acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2...

 vs JWH-007
JWH-007
JWH-007 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It was the most active of the first group of N-alkyl naphoylindoles discovered by the team led by John W Huffman, several years after the family was initially...

, JWH-081
JWH-081
JWH-081 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. With a Ki of 1.2nM it is fairly selective for the CB1 subtype, its affinity at this subtype approximately 10x the affinity at CB2. It was discovered by and named...

 vs JWH-098
JWH-098
JWH-098 is a synthetic cannabinoid receptor agonist from the naphthoylindole family. It is the indole 2-methyl derivative of a closely related compound JWH-081, but has markedly different affinity for the CB1 and CB2 receptors...

).
Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid, Org 28611
Org 28611
Org 28611 is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors...

, but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as in JWH-200
JWH-200
JWH-200 is an analgesic chemical from the aminoalkylindole family, which acts as a cannabinoid receptor agonist. Its binding affinity at the CB1 receptor is 42nM, around the same as that of THC, but its analgesic potency in vivo was higher than that of other analogues with stronger CB1 binding...

 or A-796,260
A-796,260
A-796,260 is a drug developed by Abbott Laboratories which acts as a potent and selective cannabinoid CB2 receptor agonist. Replacing the aromatic 3-benzoyl or 3-naphthoyl group found in most indole derived cannabinoids with the 3-tetramethylcyclopropylmethanone group, imparts significant...

. Early compounds such as these have subsequently led to the development of a large number of related indole-3-carboxamide cannabinoid ligands.

See also

  • A-834,735
    A-834,735
    A-834,735 is a drug developed by Abbott Laboratories which acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors, with a Ki of 12nM at CB1 and 0.21nM at CB2...

  • AB-001
    AB-001
    AB-001 or 1-pentyl-3-indole is a designer drug which was found as an ingredient in synthetic cannabis smoking blends in Ireland in 2010 and Hungary in 2011...

  • AM-1221
    AM-1221
    AM-1221 is a drug which acts as a potent and selective agonist for the cannabinoid receptor CB2, with a Ki of 0.28nM at CB2 and 52.3nM at the CB1 receptor, giving it around 180x selectivity for CB2. The 2-methyl and 6-nitro groups on the indole ring both tend to increase CB2 affinity while...

  • JTE 7-31
    JTE 7-31
    JTE 7-31 is a selective cannabinoid receptor agonist invented by Japan Tobacco. It is a reasonably highly selective CB2 agonist, but still retains appreciable affinity at CB1, with a Ki of 0.088nM at CB2 vs 11nM at CB1.-See also:* A-834,735* JTE-907...

  • MDA-19
    MDA-19
    MDA-19 is a drug which acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species...

  • (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone
    (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone
    -methanone is a drug invented by Abbott Laboratories, that acts as a selective full agonist of the peripheral cannabinoid receptor CB2, but with much lower affinity for the psychoactive CB1 receptor. It has high affinity for the CB2 receptor with a Ki of 1.8nM but 83x lower affinity for the CB1...


Further reading

1. John Hynes., Katerina Leftherisa, Hong Wua, Chennagiri Pandita, Ping Chena, Derek J. Norrisa, Bang-Chi Chenb, Rulin Zhaob, Peter A. Kienerc, Xiaorong Chenc, Lori A. Turkc, Vina Patil-Kootac, Kathleen M. Gilloolyc, David J. Shuterc and Kim W. Mclntyrec. C3 AMIDO-INDOLE CANNABINOID RECEPTOR MODULATORS. Bioorganic and Medical Chemistry Letters. Volume 12 issue 17, 2 September 2002 pages 2399-2402

2. Frost, J. M.; Dart, M. J.; Tietje, K. R.;
Garrison, T. R.; Grayson, G. K.; Daza,
A. V.; El- Kouhen, O. F.; Yao, B. B. et al.
(2010) . "Indol -3-ylcycloalkyl Ketones:
Effects of N1 Substituted Indole Side
Chain Variations on CB2 Cannabinoid
Receptor Activity" . Journal of Medicinal
Chemistry 53 (1 ): 295. doi :10.1021/
jm901214q . PMID 19921781

3. Chin CL, Tovcimak AE, Hradil VP,
Seifert TR, Hollingsworth PR,
Chandran P, Zhu CZ, Gauvin D, Pai M,
Wetter J, Hsieh GC, Honore P, Frost JM,
Dart MJ, Meyer MD, Yao BB, Cox BF,
Fox GB (January 2008). "Differential
effects of cannabinoid receptor
agonists on regional brain activity
using pharmacological MRI" . British
Journal of Pharmacology 153 (2) : 367–
79. doi :10.1038/ sj.bjp .0707506 .
PMC 2219521 . PMID 17965748
The source of this article is wikipedia, the free encyclopedia.  The text of this article is licensed under the GFDL.
 
x
OK